Correlation between contrast enhancement on intraoperative magnetic resonance imaging and histopathology in glioblastoma

Pieter L Kubben, Pieter Wesseling, Martin Lammens, Olaf E M G Schijns, Mariël P Ter Laak-Poort, Jacobus J van Overbeeke, Henk van Santbrink, Pieter L Kubben, Pieter Wesseling, Martin Lammens, Olaf E M G Schijns, Mariël P Ter Laak-Poort, Jacobus J van Overbeeke, Henk van Santbrink

Abstract

Object: Glioblastoma is a highly malignant brain tumor, for which standard treatment consists of surgery, radiotherapy, and chemotherapy. Increasing extent of tumor resection (EOTR) is associated with prolonged survival. Intraoperative magnetic resonance imaging (iMRI) is used to increase EOTR, based on contrast enhanced MR images. The correlation between intraoperative contrast enhancement and tumor has not been studied systematically.

Methods: For this prospective cohort study, we recruited 10 patients with a supratentorial brain tumor suspect for a glioblastoma. After initial resection, a 0.15 Tesla iMRI scan was made and neuronavigation-guided biopsies were taken from the border of the resection cavity. Scores for gadolinium-based contrast enhancement on iMRI and for tissue characteristics in histological slides of the biopsies were used to calculate correlations (expressed in Kendall's tau).

Results: A total of 39 biopsy samples was available for further analysis. Contrast enhancement was significantly correlated with World Health Organization (WHO) grade (tau 0.50), vascular changes (tau 0.53), necrosis (tau 0.49), and increased cellularity (tau 0.26). Specificity of enhancement patterns scored as "thick linear" and "tumor-like" for detection of (high grade) tumor was 1, but decreased to circa 0.75 if "thin linear" enhancement was included. Sensitivity for both enhancement patterns varied around 0.39-0.48 and 0.61-0.70, respectively.

Conclusions: Presence of intraoperative contrast enhancement is a good predictor for presence of tumor, but absence of contrast enhancement is a bad predictor for absence of tumor. The use of gadolinium-based contrast enhancement on iMRI to maximize glioblastoma resection should be evaluated against other methods to increase resection, like new contrast agents, other imaging modalities, and "functional neurooncology" - an approach to achieve surgical resection guided by functional rather than oncological-anatomical boundaries.

Keywords: Glioblastoma; image guided surgery; intraoperative magnetic resonance imaging; neurooncology; neuropathology.

Figures

Figure 1
Figure 1
Kaplan–Meier curve displaying postoperative survival
Figure 2
Figure 2
Interobserver agreement for each tumor parameter expressed in kappa-squared (CI = confidence interval)
Figure 3
Figure 3
Web diagram demonstrating sensitivity and specificity of contrast enhancement (using two definitions) for all significantly correlated tumor parameters

References

    1. Claes A, Idema AJ, Wesseling P. Diffuse glioma growth: A guerilla war. Acta Neuropathol. 2007;114:443–58.
    1. Duffau H. Surgery of low-grade gliomas: Towards a ‘functional neurooncology’. Curr Opin Oncol. 2009;21:543–9.
    1. Duffau H. The challenge to remove diffuse low-grade gliomas while preserving brain functions. Acta Neurochir (Wien) 2012;154:569–74.
    1. Ekinci G, Akpinar IN, Baltacioğlu F, Erzen C, Kiliç T, Elmaci I, et al. Early-postoperative magnetic resonance imaging in glial tumors: Prediction of tumor regrowth and recurrence. Eur J Radiol. 2003;45:99–107.
    1. Fan G, Sun B, Wu Z, Guo Q, Guo Y. In vivo single-voxel proton MR spectroscopy in the differentiation of high-grade gliomas and solitary metastases. Clin Radiol. 2004;59:77–85.
    1. Hall WA, Truwit CL. Intraoperative MR-guided neurosurgery. J Magn Reson Imaging. 2008;27:368–75.
    1. Holodny AI, Makeyev S, Beattie BJ, Riad S, Blasberg RG. Apparent diffusion coefficient of glial neoplasms: Correlation with fluorodeoxyglucose-positron-emission tomography and gadolinium-enhanced MR imaging. AJNR Am J Neuroradiol. 2010;31:1042–8.
    1. Hunt MA, Bago AA, Neuwelt EA. Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors by using ferumoxtran-10. AJNR Am J Neuroradiol. 2005;26:1084–8.
    1. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 1987;66:865–74.
    1. Kubben PL, Meulen Ter KJ, Schijns OE, Laak-Poort Ter MP, van Overbeeke JJ, Santbrink HV. Intraoperative MRI-guided resection of glioblastoma multiforme: A systematic review. Lancet Oncol. 2011;12:1062–70.
    1. Kubben PL, Postma AA, Kessels AG, van Overbeeke JJ, van Santbrink H. Intraobserver and interobserver agreement in volumetric assessment of glioblastoma multiforme resection. Neurosurgery. 2010;67:1329–34.
    1. Kubben P, van Santbrink H. Glioblastoma resection. J Neurosurg. 2012;116:1163–4. author reply 1167-8.
    1. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190–8.
    1. Lang FF, Sawaya R, Suki D, Mccutcheon IE, Hess KR. Letter to the editor: Glioblastoma resection. J Neurosurg. 2012;116:1166–7.
    1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.
    1. Martin AJ, Hall WA, Liu H, Pozza CH, Michel E, Casey SO, et al. Brain tumor resection: Intraoperative monitoring with high-field-strength MR imaging-initial results. Radiology. 2000;215:221–8.
    1. Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, et al. Biospecimen reporting for improved study quality (BRISQ) Cancer Cytopathol. 2011;119:92–101.
    1. Neuwelt EA, Várallyay P, Bagó AG, Muldoon LL, Nesbit G, Nixon R. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours. Neuropathol Appl Neurobiol. 2004;30:456–71.
    1. Neuwelt EA, Varallyay CG, Manninger SN, Solymosi DN, Haluska M, Hunt MA, et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy. Neurosurgery. 2007;60:601–12.
    1. Nimsky C, Ganslandt O, Buchfelder M, Fahlbusch R. Glioma surgery evaluated by intraoperative low-field magnetic resonance imaging. Acta Neurochir Suppl. 2003;85:55–63.
    1. Noël G, Guillevin R. Delineation of glioblastoma, simplicity to complexity, the contribution of imaging. Cancer Radiother. 2011;15:484–94.
    1. Piccirillo SG, Dietz S, Madhu B, Griffiths J, Price SJ, Collins VP, et al. Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin. Br J Cancer. 2012;107:462–8.
    1. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome 2008;62:753-64. Neurosurgery. 2008;62:753–64. discussion 264-6.
    1. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115:3–8.
    1. Schneider JP, Trantakis C, Rubach M, Schulz T, Dietrich J, Winkler D, et al. Intraoperative MRI to guide the resection of primary supratentorial glioblastoma multiforme: A quantitative radiological analysis. Neuroradiology. 2005;47:489–500.
    1. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance and extent of resection in glioma surgery: A randomised, controlled trial. Lancet Oncol. 2011;12:997–1003.
    1. Solheim O, Jakola AS, Gulati S, Salvesen O. Letter to the editor: Glioblastoma resection. J Neurosurg. 2012;116:1164–6.
    1. Stupp R, Hegi ME, Mason WP, den Bent van MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.
    1. Stupp R, Mason WP, den Bent van MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
    1. Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, et al. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2012;70:234–43. discussion 243-4.
    1. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–72.
    1. Widhalm G, Minchev G, Woehrer A, Preusser M, Kiesel B, Furtner J, et al. Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies. Neurosurg Rev. 2012;35:381–91.
    1. Willems PW, Taphoorn MJ, Burger H, Berkelbach van der Sprenkel JW, Tulleken CA. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-enhancing tumors: A randomized controlled trial. J Neurosurg. 2006;104:360–8.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel